About Rhinomed
Rhinomed was founded in Melbourne, Australia in 2013 when Michael Johnson became CEO of a listed medical technology company.
During 2013 and 2014 he developed the Rhinomed nasal technology platform and set out our strategy of launching in the global consumer health, diagnostics and eventually nasal drug delivery markets.
Since 2013 Rhinomed has steadfastly focused on the execution of this strategy. Today Rhinomed sells its technology across three continents in leading pharmacy stores and online via Amazon and other ecommerce channels.
The company was listed in 2007 and privatised in 2025. Rhinomed Health Corporation is a US based company with offices in Stratford, USA and Melbourne, Australia.
Board
The Rhinomed story
From a simple idea to a global solution for better breathing, here’s how Mute and Turbine came to life.
2013
The birth of Rhinomed
When Michael Johnson took the helm of ailing ASX listed biotech company Consegna, the business was in need of a radical new direction. Recognising the untapped potential in respiratory and nasal health, the company rebranded as Rhinomed Limited, a name that would soon become synonymous with innovation in breathing technology, with a vision to create a portfolio of products that would redefine how people breathe, sleep, maintain their health and diagnose disease.
2014
Turbine launches
Rhinomed’s first breakthrough came with the launch of Turbine, a nasal dilator clinically shown to increase airflow by an average of 38%. Originally targeted at athletes, Turbine quickly gained traction among elite athletes and Olympians, including Tour de France champion Chris Froome, for its ability to enhance breathing and recovery during intense physical exertion.
2015
The snoring spin-off: Mute
Building on Turbine’s momentum, the team turned their attention to one of the world’s most persistent sleep issues: snoring. The result was Mute, a discreet, adjustable nasal device that gently expands the nasal passages, encouraging nasal breathing and significantly reducing snoring.
2016
Mute takes off
Mute’s success was immediate, rapidly becoming the fastest-growing brand in the US nasal snoring market and earning acclaim for its user-centric design and effectiveness.
2020
Global shutdown
Covid hits in 2020, and the world changes. Mute helps users breathe behind their masks, and Rhinomed uses its expertise in comfortable nasal devices to turn the technology to helping test for respiratory viruses. The Rhinoswab begins development, and later spawns the Rhinoswab Junior, the new preferred method for paediatric sample collection thanks to its comfort and efficacy.
2024
Mute Mouth Tape launches
A growing number of customers tell us that they’ve taken to taping their mouths to ensure that they’re breathing fully through their nose. We’re not satisfied with other options on the market, so develop a tape of our own. We take it from idea to store shelves in a matter of months, and our skin-friendly Mouth Tape is ready to pair with your Nasal Dilators.
2026
A growing mission
From snoring and sleep to performance and wellness, Mute continues to innovate with breathing at the core of better living. Rhinoswab and Rhinoswab Junior are beginning to receive regulatory approval and Rhinomed has other new products in the pipeline to help you breathe and sleep better. Today, Rhinomed’s products are shipped to thousands of stores worldwide, and the company is recognised for its relentless pursuit of innovation and commitment to improving global health outcomes. Stay tuned for more.
Investors
Rhinomed Health Corporation is privately held. Shareholder information is managed on Cake.